Linezolid and Quinupristin/Dalfopristin: Novel Antibiotics for Gram-Positive Infections of the Skin

August 2003 | Volume 2 | Issue 4 | Original Article | 378 | Copyright © August 2003

Eric S. Schweiger, MD; Noah S. Scheinfeld, MD; Hillarie R. Tishler, BA and Jeffrey M. Wienberg, MD

Abstract
With the continuing development of clinical drug resistance among bacteria, the need for new, effective agents to treat multi-drug-resistant Gram-positive infections remains important. With treatment options limited, it has become critical to identify antibiotics with novel mechanisms of activity. Several new drugs have emerged as possible therapeutic alternatives. This review focuses on agents newly introduced and FDA-approved for the treatment of skin and skin structure infections: linezolid and quinupristin/dalfopristin.